This research proposes that K2's significant adverse result incidence is due, a minimum of partly, to unique JWH-018 metabolite action within the cannabinoid one receptor (CB1R), and suggests that metabolites of most medications, although not the carboxy metabolite, retain in vitro and in vivo action at CB1Rs. Our in vitro https://am-220142086.blog-gold.com/38586546/what-does-am-2201-mean